Company Overview
Bon Natural Life Limited operates within the Basic Materials sector, specifically focusing on the Specialty Chemicals industry, where it engages in the research, development, manufacture, and sale of functional active ingredients extracted from natural herb plants across the People's Republic of China, Europe, North America, and the Middle East. This sector classification indicates that the company derives its primary value from raw material processing and chemical synthesis, serving markets that require specialized compounds for various applications. The company currently maintains a market capitalization of $13.83M, generates annual revenue of $18.67M, and employs 96 individuals to support its operational activities. These financial figures suggest that Bon Natural Life Limited is a small-cap entity with a revenue base that aligns closely with its market valuation, indicating a company that is likely in an early stage of its lifecycle or operating with a niche product focus rather than broad market dominance.
Financial Health
The company reported revenue of $18.67M over the trailing twelve months, yet recorded a net income loss of $-1,994,768, revealing a significant cost structure where expenses substantially exceed gross profits before interest and taxes. EBITDA for the period stands at $-535,580, which highlights that while operating cash generation from core activities is negative, the loss is not as severe as the bottom-line net income suggests due to non-cash charges. Free cash flow is negative at $-5,943,853, indicating that the company is burning cash faster than it generates it from operations, which limits its current financial flexibility and ability to fund expansion without external capital. Gross margin is 20.8%, suggesting that the company retains a moderate portion of revenue after the direct cost of goods sold, while the operating margin of -17.8% and profit margin of -10.7% demonstrate that overhead costs and other expenses are eroding profitability significantly. The balance sheet shows a cash position of $3.77M against total debt of $12.42M, resulting in a debt-to-equity ratio of 21.41, which characterizes the company as highly leveraged with liabilities significantly outweighing equity. Despite the high leverage, the current ratio is 1.74, indicating that the company possesses 1.74 times more current assets than current liabilities, suggesting a conservative stance on short-term liquidity management relative to its immediate obligations. Return on equity is -4.0% and return on assets is -1.4%, metrics that reveal that management effectiveness is currently negative, as the company is generating losses on both the shareholders' equity and the total asset base utilized to generate revenue.
Valuation Assessment
The trailing P/E ratio is listed as N/A due to the negative earnings, whereas the forward P/E is 2.34, implying that the market prices the stock based on anticipated future profitability rather than current performance. The price-to-book ratio stands at 0.15, indicating that the market values the company at a fraction of its book value, suggesting a lack of market premium over the tangible assets listed on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 0.74 and the EV/EBITDA of -32.66 provide further context, with the negative EV/EBITDA reflecting the company's current lack of earnings power and reliance on asset value or future recovery for valuation support. The 52-week high is $4.75 and the 52-week low is $1.14, establishing a trading range where the current price sits significantly below the recent highs, reflecting investor caution regarding the company's financial trajectory. The beta value is -0.35, which is an unusual negative figure indicating that the stock price tends to move inversely to the broader market or exhibits volatility patterns distinct from the general market index.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both N/A, meaning there is no historical data available to compare current performance against the prior year, preventing a direct analysis of whether earnings are growing faster or slower than revenue. Consequently, the dividend yield is N/A and the payout ratio is 0.0%, confirming that the company does not distribute dividends to shareholders. As a non-dividend payer, the company reinvests its earnings—or in this case, manages its cash reserves—into growth initiatives rather than paying out income to investors. The overall growth and income profile is characterized by a lack of historical growth data and a complete absence of dividend income, reflecting a capital-intensive or early-stage business model focused on operational recovery rather than shareholder returns.